Increased Sialylation of Anti-Thomsen-Friedenreich Antigen (CD176) Antibodies in Patients with Gastric Cancer: A Diagnostic and Prognostic Potential
Table 3
Distribution of cancer patients by stage of disease, tumor morphology, and gender in subgroups stratified by TF-specific antibody reactivity to SNA and anti-TF IgM level.
Group of patients
SNA/IgM subgroup
1
2
3
4
SNA≥IgM≥
SNA<IgM≥
SNA≥IgM<
SNA<IgM<
124*
25
37
36
26
Stage 1
43
8 (18.6)
14 (32.2)
13 (30.2)
8 (18.6)
Stage 2
28
7 (25.0)
7 (25.0)
8 (28.6)
6 (21.4)
Stage 3
39
7 (17.9)
13 (33.3)
12 (30.7)
7 (17.9)
Stage 4
14
3 (21.4)
3 (21.4)
3 (21.4)
5 (35.7)
DT
49
11 (22.4)
16 (32.7)
14 (28.6)
8 (16.3)
IT
73
14 (19.2)
19 (26.0)
22 (30.1)
18 (24.6)
males
70
15 (21.7)
18 (25.7)
20 (28.6)
17 (24.3)
females
54
10 (18.5)
19 (35.2)
16 (29.6)
9 (16.7)
Two patients had morphologically mixed (unclassified) tumors. In brackets: the percentage in the corresponding group.
